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Abstract
OBJECTIVES: Adjuvant chemotherapy with vinorelbine plus cisplatin (VC) improves survival in resected non-small-cell lung
cancer (NSCLC), but has negative impact on quality of life (QoL). In advanced NSCLC, gemcitabine plus cisplatin (GC) and docetaxel
plus cisplatin (DC) exhibit comparable efficacy, with possibly superior QoL compared to VC. This trial investigated these regimens in the
adjuvant setting.
METHODS: Patients with Stage IB to III NSCLC were eligible following standardized surgery. Overall, 136 patients were included, with 67
and 69 assigned to the GC and DC arms, respectively. Cisplatin (75 mg/m2, Day [D] 1) plus gemcitabine (1250 mg/m2, D1 and D8) or doce-
taxel (75 mg/m2 D1) were administered for three cycles. Primary end-point was QoL (EORTC QLQ-C30), with the study designed to detect
a 10-point difference between arms. Overall survival, safety and cost were secondary end-points.
RESULTS: No between-group imbalance was observed in terms of patient characteristics. At inclusion, global health status (GHS) scores
(/100) were 63.5 and 62.7 in GC and DC, respectively (P = 0.8), improving to 64.5 and 65.4 after 3 months (P = 0.8). No significant difference
in functional or symptoms scores was observed between the arms except for alopecia. Grade 3/4 haematological and non-haematological
toxicities were found in 33.8 and 21.7% (P = 0.11), and 33.8 and 26.1% (P = 0.33) of patients, in GC and DC, respectively. At 2 years, 92.9
and 89.8% of patients remained alive in GC and DC, respectively (P = 0.88).
CONCLUSIONS: DC and GC adjuvant chemotherapies for completely resected NSCLC were well tolerated and appear free of major QoL
effects, and are therefore representing candidates for comparison with the standard VC regimen.
Keywords: Non-small-cell lung cancer • Adjuvant chemotherapy • Quality of life
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INTRODUCTION
Only 15–20% of lung cancer cases are diagnosed at an early stage
and thus make the patient eligible for thoracic surgery, such as
lobectomy or pneumonectomy plus radical lymph node dissec-
tion. However, 5-year survival rates for patients with pathological-
ly staged IA-IIB non-small-cell lung cancer (NSCLC) average 50%,
and adjuvant chemotherapy is the standard of care for patients
with Stage II–III resected NSCLC [1, 2], with an absolute benefit of
5.4% at 5 years, especially when using vinorelbine plus cisplatin
(VC) [3–5].
While the benefit of adjuvant chemotherapy has been demon-
strated, the optimal regimen remains to be established. Long-term
side-effects have been singled out in the older regimens [6], and
the VC combination is associated with a negative impact on
quality of life (QoL), although it does improve survival in patients
with resected NSCLC [7]. In advanced-stage NSCLC, gemcitabine
plus cisplatin (GC) and docetaxel plus cisplatin (DC) combinations
have comparable efficacy and may be superior to VC in terms of
QoL outcomes.
This trial was therefore designed to provide data, and especially
data on QoL outcomes, on GC and DC adjuvant regimens for
patients with resected NSCLC, in order to select a potential new
comparator to the VC regimen.
MATERIALS ANDMETHODS
Global study design
This study was designed in 2003 as a randomized trial of adjuvant
GC versus DC regimens after complete resection of Stage IB–III
NSCLC with the objective to eventually select the regimen with the
lower impact on postoperative QoL. It began in September 2004.
The protocol was conducted in accordance with the Helsinki
Declaration and Good Clinical Practice guidelines, and was
approved by the Comité de Protection des Personnes Marseille 2
(French ethics review board) in September 2004. All patients
signed written informed consent before enrolment. Because
patient enrolment began before 1 November 2006, the trial was
not registered on the clinical trials website. However, the method-
ology was published at the time of the initiation of the trial [8].
Patient eligibility
Patients aged 18–75 years with completely resected (R0) Stage IB–
III NSCLC in addition to an Eastern Cooperative Oncology Group
performance status of 0 or 1 were eligible for entry into this study.
Surgery was standardized on the following basis. First, anatomical
resection with lobectomy or pneumonectomy was defined as the
standard resection for fit patients, thus excluding sublobar resec-
tions, that is, segmentectomy and wedge resections. Secondly, re-
inforcement of the main-stem bronchial suture line was carried
out as a matter of routine in cases of right pneumonectomy.
Thirdly, routine mediastinal lymphadenectomy was considered an
essential component of NSCLC thoracic surgery. Operative reports
were also required to include the following information: descrip-
tion of the tumour and its connections with surrounding anatom-
ical structures; surgeon’s justification for the choice of resection
performed; completeness of the resection; lymph node stations
dissected according to the staging criteria of the American Joint
Committee on Cancer [9].
Patients were required to have adequate bone marrow reserve
and organ function, including calculated creatinine clearance of
45 ml/min based on the standard Cockcroft and Gault formula.
Patients with severe postoperative complications (acute respira-
tory distress syndrome, bronchial fistula or severe pneumonia)
were ineligible. Patients with previous history of cancer within the
previous 5 years or clinically significant cardiac dysfunction, active
infection or neurological/psychiatric disorders were also excluded
from participating in the study.
Treatment plan
Within 6 weeks after the standardized thoracic surgery, eligible
patients were randomly assigned in a 1:1 ratio to adjuvant GC or
DC chemotherapy. Stratification was done according to the patho-
logical tumour-node-metastasis (pTNM) staging as being in Stages
IB, II or III and centre.
Treatment started within 2 weeks of randomization. Consequently,
chemotherapy was started no more than 8 weeks after surgery and
consisted of cisplatin (75 mg/m2, D1) plus gemcitabine (1250 mg/m2,
D2 and D8) or docetaxel (75 mg/m2, D1) for three cycles. At the time
of the trial design, the number of postoperative chemotherapy cycles
was not firmly determined and three cycles were deemed to be
sufficient as in the NATCH trial design. Eligible patients received
a platinum-based doublet with 75 mg/m2 cisplatin on Day (D) 1
plus either 1250 mg/m2 gemcitabine on D1 and D8 or 75 mg/m2
docetaxel on D1 every 3 weeks for a maximum of three cycles.
Chemotherapy was adjusted for toxicity according to protocol guide-
lines. Patients requiring a reduction in the gemcitabine, docetaxel or
cisplatin doses received on D1 were given the reduced dose for the
remainder of the study. Therapy was discontinued in patients who,
after already having had two dose reductions since their initial D1
dose, experienced toxicity requiring a third dose reduction. Cycle
delays of up to 35 days were permitted for recovery from adverse
events. Supportive therapies, such as erythropoietic agents or gran-
ulocyte colony-stimulating factors, were permitted according to
the American Society of Clinical Oncology (ASCO) guidelines.
Postoperative radiotherapy for patients with pN2 disease was not
mandatory, this decision being left to the participating centre.
Postoperative radiotherapy had to be decided on prior to patients’ in-
clusion in the trial. Radiotherapy was allowed at doses ranging from
45 to 60 Gy, 2 Gy per fraction, with five fractions per week, starting
4 weeks after the end of chemotherapy.
Baseline and follow-up assessments
QoL was assessed using the EORTC QLQ-C30 and the lung cancer
questionnaire module QLQ-LC13, two validated QoL tools avail-
able in French [10–14]. The QLQ-C30 comprises 30 questions cov-
ering five functional scales (physical, role, emotional, cognitive
and social), three symptom scales (fatigue, pain and nausea/
vomiting) and a global health status (GHS)/QoL scale, as well as six
single items (dyspnoea, insomnia, appetite loss, constipation, diar-
rhoea and financial difficulties). Raw scores from each functional
and symptom scale were translated onto an overall scale ranging
from 0 to 100. Higher functional scores were indicative of better
QoL, whereas lower symptom and single item scores reflected
fewer symptoms. Patients were asked to complete a baseline QoL
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assessment within the 14 days of screening and then at Weeks 1
(start of chemotherapy), 3 (D1 cycle 2), 6 (D1 cycle 3) and 9 (end
of chemotherapy) during chemotherapy, at months 3, 6 and 12
after randomization, at scheduled clinic appointments.
Before entering the study, patients underwent a physical exam-
ination and radiological assessment by CT (computed tomog-
raphy) scan of the chest, upper abdomen and brain. Physical
examinations and chest X-rays were performed at D1 of each
chemotherapy cycle. The follow-up clinical examinations and
radiological assessment (alternately chest X-ray and CT scan of the
chest, upper abdomen and brain) were performed 4 weeks after
the end of treatment and then every 3 months for 2 years, and
every 6 months thereafter for up to 5 years. All patients who
received at least one dose of cisplatin plus either gemcitabine or
docetaxel were considered assessable for safety. Patients were
assessed for toxicity according to the National Cancer Institute
Common Toxicity Criteria, version 2.0 (http://ctep.cancer.gov/
protocoldevelopment/electronic_applications/docs/ctcaev2.pdf.l).
Efficacy analyses incorporated all enrolled patients on an intent-
to-treat basis.
Statistical analyses
The primary end-point was QoL, assessed 3 weeks after the end of
chemotherapy (evaluation at the end of chemotherapy at Week 9)
using the Quality of Life Questionnaire EORTC QLQ-C30. The trial
was designed to detect a 10-point difference in QoL scores on the
global scale (α = 0.05, power 80%) between the arms. Secondary
end-points included overall survival (OS), disease-free survival
(DFS), toxicity and costs. Cost data will be presented separately.
Compliance with QoL data collection was expressed as the per-
centage of eligible patients expected to complete the QoL ques-
tionnaire at a certain time point. Patients were censored in the
event of disease relapse or death from any cause.
A change in score of 10 points from baseline was defined as
clinically significant on the basis of previous studies [7] and pub-
lished guidelines [15, 16]. A sample size of 63 patients per arm
(i.e. 126 patients in total) was required to provide the trial with
80% power in order to detect a 10-point difference in QoL score
between the two adjuvant chemotherapy arms, with a two-sided
5% significance level. The sample size was increased by 10% to
150 patients taking in order to minimize the impact of patients
lost to the follow-up. Accrual in the trial was prematurely stopped
by the steering committee in December 2007 following the
release of new ASCO recommendations, which proposed four
cycles of adjuvant therapy as the standard, and excluding patients
with Stage pIB from adjuvant chemotherapy.
The χ2test was performed in order to compare data between
the two study arms. The Wilcoxon rank-sum test was used to
compare changes between treatment arms in QoL score at each
assessment time from baseline. The Kaplan–Meier product-limit
method was used to summarize DFS and OS distributions. All tests
on treatment effects were two-sided, unless otherwise stated.
RESULTS
Patients
Between August 2004 and December 2007, 136 patients with
resected NSCLC and without major postoperative complications
were enrolled in the study from 10 institutions. Figure 1 illustrates
the flow diagram of the study. The median age was 57 years, with
74% of the patients being male (Table 1). The study was prematurely
closed by the steering committee, but more than the required 126
patients had been included, allowing for full analysis of the trial.
As regards the TNM classification, 32% of patients were staged
IB, 34% were staged II and 34% were staged III. In terms of hist-
ology, 55% of patients exhibited adenocarcinomas, whereas 23%
exhibited squamous cell carcinomas. The remaining patients
showed other histological types. In 85% of cases, surgery consisted
of (bi)lobectomy. Out of the total number of patients, 67 were
assigned to the GC arm and 69 to the DC arm. No significant dif-
ference was observed in terms of patient characteristics between
the two arms, as given in Table 1.
Quality of life
Compliance with QoL assessment was 100% at baseline, 98% at
C1D1 (Week 1), 95% at C2D1 (Week 3), 86% at C3D1 (Week 6) and
71% at the end of chemotherapy (Week 9), meaning that for these
patients, the QoL questionnaires were properly filled out, com-
plete and suitable for evaluation.
At inclusion, GHS scores (/100) were 63.5 in the GC arm and 62.7
in the DC arm (P = 0.8), improving to 64.5 and 65.4, respectively, after
the 3-month treatment period (P = 0.8) (Fig. 2). Similarly, for the other
functional scores, there were no significant differences between the
two treatment groups. The social function was not altered by the
number of infusions (Days 1 and 8 for the GC arm) as attested by
Fig. 2. In terms of symptom scores, there were no significant
between-group differences except for alopecia, where the DC arm
showed a significantly higher score than the GC arm (Figs 3 and 4).
Compliance with QoL assessment after 12 months was too low
to allow any conclusion (data not shown).
Safety
Chemotherapy compliance was satisfactory, with 80.6 and 85.5%
of the patients in the GC and DC arms, respectively, completing all
the three planned cycles of chemotherapy.
Overall, 32.8 and 21.7% of patients in the GC arm and the DC
arm, respectively, experienced Grade 3/4 haematological toxici-
ties, with no significant difference observed between the arms
(Table 2). A significant difference was observed for alopecia only
with 13.0% of patients affected in the DC arm versus 3.0% in the
GC arm (Table 2).
Overall survival
The median follow-up for the two arms was 20.2 months. At 1
year, 100 and 96.8% of patients remained alive in the GC and DC
arms, respectively, this figure being reduced to 92.9 and 89.8%
after 2 years (P = 0.88), yielding no significant difference between
the two arms (log-rank) (Fig. 5). In the course of the study, 15
deaths occurred, 7 in the GC arm and 8 in the DC arm.
DISCUSSION
Adjuvant chemotherapy is now considered to be a standard
of care in stage II and III completely resected NSCLC [2].
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Nonetheless, the optimal regimen has yet to be determined
while the VC regimen remains the most widely used and the
current trial assessed two other alternative regimens, GC and
DC. While the comparison between these regimens with VC
would be interesting, the oncological community is now
favouring molecular-based or targeted therapy-based adjuvant
trials. Therefore, the funding, accrual and adhesion to any large
trial comparing two chemotherapy regimens is unlikely, thus
reinforcing the need to publish already available data in this
setting. The presented data show that GC and DC are feasible
adjuvant chemotherapy regimens with good compliance for
completely resected NSCLC patients. These regimens translate
into comparable outcomes in terms of QoL and efficacy, and
show acceptable safety profiles. Despite some reservations
stemming from cross-trial comparisons, our study supports the
possible use of GC or DC as an adjuvant regimens, especially
when considering their QoL impact as compared with the VC
regimen.
QoL is a crucial parameter in the assessment of cancer treat-
ment strategies, especially when comparing very similar
therapies. It is however difficult to assess and measure object-
ively. We used standardized and the well-accepted dedicated
EORTC QLQC30 and LC13 questionnaires. As done in most
studies dealing with QoL based upon these questionnaires, we
looked at absolute values, but did not consider the net
changes in score in comparison with the baseline. The 6- to
8-week delay for adjuvant chemotherapy was considered as an
inclusion criterion, meaning that none of the patients received
adjuvant chemotherapy sooner than 6 weeks and later than 8
weeks after surgery. This clause obviously led to select a subset
of fit patients in whom surgery by itself did not impact early
QoL that much, because patients having had any significant
postoperative complication were not included in the trial.
Therefore, the exact time between surgery and start of chemo-
therapy was not collected nor analysed as a factor potentially
affecting QoL in both arms due to this limitation. Another limi-
tation is linked to the multi-institutional design of the study.
We can only speculate that patients enrolled in each centre
received similar perioperative management, especially for pain
control and postoperative rehabilitation, in adherence with
current national care guidelines. However, baseline QoL values
were not significantly different between treatment arms, thus
suggesting similar levels of independence, mobility and
freedom from main disabling symptoms. None of the patients
in the present study received video-assisted thoracic surgery
(VATS) or robot-assisted thoracic surgery (RATS) given that
available national guidelines at that time recommended to
limit the use of minimally invasive techniques to patients with
stage IA NSCLC. Finally, the small size of the overall cohort
precluded any sub-group analysis to look at the effect of the
adjuvant therapy on QoL according to some relevant charac-
teristics such as the extent of lung resection (lobectomy
vs pneumonectomy), histology or pathological stage, age and
co-morbidities.
When compared with preoperative status, QoL in patients with
resected NSCLC may be adversely affected during 3–6 months
following thoracic surgery, with a complete recovery within 6–12
months. Adjuvant chemotherapy may additionaly affect QoL for
a various length of time [8]. The data reported here suggest that
recovery may be delayed, but otherwise not seriously affected,
by GC- or DC-based adjuvant chemotherapy. It seems to be also
true in elderly patients as reported recently [17]. Interestingly,
the QoL was not differentially influenced by the number of infu-
sion, the rate of adverse events, confirming that QoL must be
considered by itself. Surprisingly, the fatigue remained stable
during the adjuvant chemotherapy maybe as a consequence of
chemotherapy while usually improving in the weeks after
surgery or an adapation to a physically compromised condition
[18]. In addition, both these regimens might be better tolerated
with a lower impact on QoL than the VC regimen [19], to be also
compared with the pemetrexed/cisplatin regimen widely used in
advanced non-squamous NSCLC and now reported in the
adjuvant setting [20]. When selecting and discussing chemo-
therapy with patients, the short-term and long-term QoL effects
of various combinations should be thoroughly addressed
and explained so as to encourage patients’ active involvement
in treatment decisions. Unfortunately, QoL issues are often
overlooked.
As shown in previous trials and meta-analyses dedicated to
stage IIIB/IV NSCLC patients, GC and DC efficacy rates seem
comparable. It should be noted, however, that survival data are
Figure 1: CONSORT flow diagram.
Table 1: Patient characteristics of each treatment arm
CDDP/GC,
n = 67 (%)
CDDP/DC,
n = 69 (%)
P-values
Male sex 50 (75) 51 (74) ns
Age, median (range) 57 [44–74] 57 [36–71] ns
Stage pIB/II/III 18 (27)/26
(39)/23 (34)
25 (36)/20
(29)/24 (35)
ns
(bi)lobectomy 56 (84) 59 (86) ns
Pneumonectomy 11 (16) 10 (14) ns
ADC/SCC/Others 33 (50)/17
(25)/17 (25)
42 (61)/15
(22)/12 (17)
ns
Minor postoperative
complications
9 (13) 11 (16) ns
ADC: adenocarcinoma; SCC: squamous cell carcinoma; GC:
gemcitabine; DC: docetaxel; CDDP: cisplatin.
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to be interpreted with caution giving the number of censored
patients. The results reported here might have been influenced
by the number of cycles planned in the treatment plan. Indeed,
as many perioperative trials designed in the same period [21, 22],
three cycles only were planned whereas four cycles of cisplatin-
based chemotherapy is now the standard. However, the influ-
ence of a difference between GC and DC of one additional
cycle on safety and QoL, although possible, is unlikely, given the
study design.
Much progress remains to be made. The future of adjuvant
chemotherapy will be shaped by individualized treatment strat-
egies based mainly on biological profiling. Useful biomarkers may
include excision repair cross-complementation group 1 (ERCC1)
for sensitivity to platinum-based therapy [23] or beta-tubulin III
for sensitivity to taxanes or vinorelbine [24]. However, individual-
ization will not be possible for all patients, and those unsuited to it
may benefit from treatment options eventually based on GC or
DC regimens.
Figure 2: Functional scores of each treatment arm as assessed by the EORTC QLQ-C30 questionnaire. Red: DC arm; blue: GC arm.
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In conclusion, DC or GC adjuvant chemotherapy for completely
resected NSCLC might be an acceptable alternative to currently
recommended combinations and might be compared with the
VC regimen. This study did not demonstrate any significant nega-
tive QoL impact of DC and GC in resected lung cancer patients,
and might be useful when discussing treatment options with such
patients.
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